← FDA DRUG APPROVALS

FDA ANDA · ANDA206173

VERAPAMIL HYDROCHLORIDE

Sponsor: CADILA PHARMS LTD

APPLICATION
ANDA206173
TYPE
ANDA
ORIGINAL APPROVAL
2017-05-05
LATEST ACTION
2020-03-27
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Prescription

Products

VERAPAMIL HYDROCHLORIDEPrescription
VERAPAMIL HYDROCHLORIDE 120MG · TABLET, EXTENDED RELEASE · ORAL
VERAPAMIL HYDROCHLORIDEPrescription
VERAPAMIL HYDROCHLORIDE 180MG · TABLET, EXTENDED RELEASE · ORAL
VERAPAMIL HYDROCHLORIDEPrescription
VERAPAMIL HYDROCHLORIDE 240MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2020-03-27Labeling · Supplement 3 · standardAP
2019-09-25Labeling · Supplement 1 · standardAP
2017-05-05UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →